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Abstract 
Antithrombotic therapy is a critical component of the management of ST-elevation myocardial 
infarction (STEMI) patients treated with primary percutaneous coronary intervention (PCI). Rapid 
and profound inhibition of platelet reactivity has been shown to mitigate the ischemic risks and 
improve myocardial salvage.   
High residual platelet reactivity (HRPR) has been reported up to 4 or 6 hours after loading dose of 
prasugrel or ticagrelor, therefore, multiple alternative strategies, including crushed or chewed oral 
tables or intravenous agents, have been investigated to provide a more rapid and sustained 
inhibition of platelet function and bridge the initial treatment gap. The FABOLUS-FASTER is the 
first investigator-initiated, multicentre, open-label, prospective, randomized study to directly 
compare the pharmacodynamics effects of cangrelor, tirofiban, chewed or integer prasugrel. This 
study will add new insights in the management of antiplatelet therapy in patients with STEMI 
undergoing primary PCI and might be hypothesis-generating for future clinical trials in this field. 
The trial is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24. 
 




































































AAR=area at risk  
AUC=area under the curve 
ACS=acute coronary syndrome 
ACT=activated clotting time 
ADP=adenosine diphosphate 
ATP=adenosine triphosphate 
cMRI=magnetic resonance imaging 
ECG=electrocardiogram 
HPRP=high residual platelet reactivity 
IPA=inhibition of platelet activity 
LTA=light transmittance aggregometry 
MS=myocardial salvage 
MSI=myocardial salvage index 
MVO=microvascular obstruction 
PAM=prasugrel active metabolite 
PCI=percutaneous coronary intervention 
PD=pharmacodynamic 
PK=pharmacokinetic 





































































Antithrombotic therapy is crucial in the management of ST-elevation myocardial infarction 
(STEMI) treated with primary percutaneous coronary intervention (PCI)[1-4]. Multiple pathways 
are involved in platelet activation, adhesion, aggregation and fibrin synthesis; hence, several anti-
thrombotics including oral and/or parenteral anti-platelet and anticoagulation agents are to be 
administered in the acute phase of STEMI[5,6]. The Facilitation through Aggrastat or cangrelor 
Bolus and infusion Over prasugreL: a mUlticenter randomized open-label trial in patientS with ST-
elevation myocardial inFarction referred for primAry percutaneouS inTERvention (FABOLUS 
FASTER) aims at investigating the acute pharmacodynamic effects of cangrelor, tirofiban or 
prasugrel, administered at standard 60 mg loading dose as integer or chewed tablets, in STEMI 
patients undergoing primary PCI.  
 
Oral P2Y12 inhibitors 
The combination of aspirin and oral inhibitors of ADP-activated platelet P2Y12 receptor such as 
prasugrel or ticagrelor has been shown to reduce ischemic recurrences as compared to aspirin and 
clopidogrel and represents the current standard of care[1-4]. However, high residual platelet 
reactivity (HRPR) has been consistently reported up to 4 or 6 hours after prasugrel or ticagrelor 
loading dose, with a large inter-individual variability[7-9]. The delayed onset and attenuated 
antiplatelet effects have been attributed to impaired drug absorption resulting in reduced drug 
bioavailability. Therefore, strategies to increase bioavailability of orally administered P2Y12 
inhibitors have been further investigated in STEMI patients, including higher loading regimens, 
which overall proved ineffective, or crushed/chewed tablets[10-16]. Two small-scale independent 
studies suggested that crushed standard loading dose of ticagrelor or prasugrel can achieve more 
pronounced platelet inhibition compared with standard whole tablets soon after drug 
administration[13,14]. The MOJITO (Mashed Or Just Integral pill of TicagrelOr) trial found that in 



































































inhibition (assessed with VerifyNow system) 1 hour after drug administration compared with 
integer tablets[13]. Similarly, the CRUSH trial enrolled 52 STEMI patients undergoing primary PCI 
and found that crushed prasugrel accelerated drug absorption, and thus, provided faster and greater 
antiplatelet effects (demonstrated by VerifyNow and whole blood vasodilator-stimulated 
phosphoprotein [VASP] assays) compared with integer tablets[14]. A pharmacokinetic analysis 
supported the pharmacodynamic findings by showing that crushed as compared to integer prasugrel 
was associated with faster drug absorption and higher plasma concentrations of prasugrel active 
metabolite (PAM) at 30 min and 1 h but not at 2 h[14]. In the IPAAD-Tica (The inhibition of 
platelet-aggregation after administration of three different ticagrelor formulations) 91 patients with 
stable angina were randomly assigned to integer, crushed or chewed ticagrelor tablets and platelet 
reactivity was assessed by VerifyNow 20 and 60 min after loading dose. Chewed ticagrelor was 
associated with significantly reduced PRU values compared with crushed or integer tablets at both 
20 and 60min, and crushed ticagrelor loading dose determined significantly lower PRU values 
compared to integer tablets at 20 min but not at 60 min[16]. 
 
Tirofiban 
Tirofiban is a small molecule, nonpeptide tyrosine derivative which belongs to the class of 
glycoprotein (GP) IIb/IIIa inhibitors (GPI) [6]. By inhibiting the binding of fibrinogen and von 
Willebrand factor to the GP IIb/IIIa receptor on the surface of the platelet, GPIs are currently 
considered the most potent inhibitors of platelet aggregation. 
A dedicated meta-analysis focusing on the benefits and risks of this drug as compared to placebo 
and abciximab has been published [17]. It included 31 studies and 20,006 patients (12,874 
comparing tirofiban versus heparin plus placebo or bivalirudin alone, and 7,132 versus abciximab). 
At 30-day, tirofiban significantly decreased mortality (OR=0.68 [0.54-0.86]; p=0.001), and death or 
myocardial infarction (MI) (OR=0.69 [0.58-0.81]; p<0.001) when compared with placebo. This 



































































thrombocytopenia. There was no difference between tirofiban and abciximab in 30-day mortality 
(OR=0.90 [0.53, 1.54]; p=0.70), while in the overall group tirofiban trended to increase the 
composite of death or MI (OR=1.18 [0.96, 1.45]; p=0.11), although this trend was not present at 
medium-term follow-up or when assessing studies using the 25µ/kg bolus of tirofiban.  
Current guidelines recommend the use of GPI, including tirofiban in selected situations[1-3].  
In the FABOLUS PRO (Facilitation through Aggrastat By drOpping or shortening Infusion Line in 
patients with ST-segment elevation myocardial infarction compared to or on top of PRasugrel given 
at loading dOse) trial, 100 STEMI patients randomly received prasugrel 60 mg versus 25 g/kg 
tirofiban bolus with or without post-bolus 2-h infusion of tirofiban, with or without concomitant 
prasugrel. Inhibition of platelet activity (IPA) at light transmittance aggregometry was performed 
throughout 24 h. Compared with prasugrel-treated patients, those in the tirofiban group had a 
significantly higher IPA to 20 mol/l ADP stimulation as (8731 vs. 3635, p<0.0001) at 30 min. 
Similarly, the degree of platelet inhibition remained suboptimal for at least 2h in prasugrel-treated 
patients. When concomitant clopidogrel was given, the post-bolus tirofiban infusion was necessary 
to maintain a high level of IPA beyond 1h. Conversely, the bolus-only tirofiban and concomitant 
prasugrel were associated with the higher and more consistent IPA levels after both ADP and 
thrombin receptor-activating peptide stimuli compared with either therapy alone. There is currently 
no head to head comparison between tirofiban and cangrelor on the degree of platelet inhibition.   
 
Cangrelor 
Cangrelor, is an intravenous reversible inhibitor of ADP-induced platelet aggregation. In most 
recent guidelines it is to be considered in P2Y12 inhibitor–naive patients undergoing PCI, including 
primary PCI, with the same class of recommendation attributed to GPI [2]. Cangrelor is an ATP 
analogue and it is meant to achieve almost complete and immediate inhibition of ADP-induced 
platelet aggregation when administered as a bolus plus infusion. The plasma half-life is 



































































of infusion[6,18-20]. After animal studies, this agent was tested in humans. In a study of 39 patients 
with unstable angina or non-Q wave myocardial infarction, who were receiving aspirin and heparin, 
cangrelor (initially identified as AR-C69931MX) was administered intravenously with stepped dose 
increments over 3 h to a plateau at either 2 g/kg/min for 21 h (Part 1; n=12) or up to 69 h (Part 2; 
n=13) or 4 g/kg/min for up to 69 h (Part 3: n=14)[21]. This study assessed safety parameters, 
platelet aggregation (PA) induced by ADP 3 mol/L (impedance aggregometry), bleeding time 
(BT) and cangrelor plasma concentrations. In patients completing the study (n=33) cangrelor was 
well tolerated. At 30-day no deaths or serious adverse events occurred, but trivial bleeding (56%) 
was frequent. Mean IPA was 36.2±39.2, 20.7±25.9 and 40.7±36.7% at 1 h post-infusion,, and 
96.0±8.6, 94.9±14.4 and 98.7±2.1% at 24 h, for Parts 1, 2 and 3 respectively. Platelet aggregation 
test was based on the whole blood impedance aggregometry (Chronolog), and the stimulation was 
done with ADP 3 mol/L. In a subsequent study, clopidogrel moderately inhibited platelet P2Y12 
receptor activation while cangrelor induced a substantially greater P2Y12 receptor inhibition[20]. In 
this study, however, the 13 patients with acute coronary syndromes (ACS) receiving cangrelor 
(Group 1; stepped dose increments of cangrelor achieving a plateau after 3 h of 2 or 4 g/kg per 
min in 8 and 5 patients, respectively), and 8 patients undergoing coronary stenting receiving 
clopidogrel (Group 2, 300 mg loading dose followed from 75 mg daily) were studied using a whole 
blood single-platelet counting aggregation assay that was collected at 30 min and 21h from infusion 
(and 69h in some patients) onset for cangrelor and 4-7 days for clopidogrel. An initial experience of 
cangrelor in patients undergoing PCI was obtained in a 2-part randomized trial comparing different 
dosages of cangrelor (1 or 2 or 4 g/kg/min for 18-24h) with placebo in 200 patients and then 
comparing cangrelor (4 g/kg/min for 18-24h) vs abciximab (0.25 mg/kg bolus followed by 0.125 
g/kg per minute up to 10 g per minute for up to 12h) in 199 patients[22]. Cangrelor was 
associated with an acceptable risk of bleeding and adverse cardiac events, and less prolongation of 



































































analysis. The CHAMPION-PLATFORM and CHAMPION-PCI trials compared cangrelor with 
placebo in clopidogrel treated patients with ACS or stable CAD undergoing PCI[23,24]. In both 
trials, cangrelor was administered with an intravenous bolus of 30 μg/kg followed by infusion of 4 
g/kg/min for at least 2h or until the conclusion of the index procedure, whichever was longer (at 
the clinician’s discretion, the infusion could be continued for 4h). In these trials, the enrolment was 
stopped when an interim analysis concluded that the trials would be unlikely to show superiority for 
the primary endpoint. The platelet function substudy of these 2 trials tested the pharmacodynamic 
effects of cangrelor vs clopidogrel and was the largest pharmacodynamic experience with cangrelor 
up to that time[19]. This study demonstrated the potent P2Y12 receptor inhibitory effects of 
cangrelor, as well as its rapid onset/offset of action based on VerifyNow analysis in 167 patients (84 
treated with cangrelor + clopidogrel and 83 treated with placebo + clopidogrel), mainly from 
CHAMPION-PCI trial. Moreover, this study included LTA assessment in 44 patients showing 
significantly greater inhibition in cangrelor-treated patients (LTA ADP 20 μM median 20.0 % vs 
69.5 %, p<0.001; and ADP 5 μM median: 2.5 % vs 49.0 %, p<0.001), but these values referred to 
the final (after 6 min) platelet aggregation not the max aggregation. An additional study tested the 
PK and PD effects of cangrelor bolus and infusion at the regimen currently used[18]. Twenty-two 
healthy volunteers were randomly assigned to 15-μg/kg bolus followed by a 2-μg/kg/min infusion 
(n=12) or 30-μg/kg bolus followed by a 4-μg/kg/min infusion (n=10) and the infusion was 
continued for 60 minutes. The higher dose provided more consistent and pronounced inhibition on 
ADP–induced P-selectin expression, but no significant differences were observed between the 2 
regimens in terms of platelet aggregation or time to recovery of platelet function. It is important to 
note that, however, this study was conducted in healthy volunteers, and again platelet aggregation 
was assessed by a whole blood test but not LTA. 
To date, there are limited data on the effects of cangrelor used in combination with oral P2Y12 
inhibitors in patients undergoing primary PCI and questions have emerged on the potential for drug-



































































generally recommended that clopidogrel and prasugrel should be administered at the end of the 
cangrelor infusion, while for ticagrelor the simultaneous administration could not be an issue, 
however, evidence on these interactions are still limited[25]. In the recent CANTIC study, 50 
STEMI patients undergoing primary PCI were randomly assigned to cangrelor or placebo (bolus 
followed by 2h infusion)[26]. All patients received crushed tablets of ticagrelor 180-mg loading 
dose at the time of cangrelor/placebo bolus administration. Pharmacodynamic analyses were 
performed at 8 time points (expressed as P2Y12 reaction units by VerifyNow and platelet reactivity 
index by vasodilator-stimulated phosphoprotein). This study supported the efficacy of cangrelor in 
bridging the gap of platelet inhibition associated with the use of oral P2Y12 inhibition induced by 
ticagrelor, without any apparent drug-drug interaction[26]. 
 
STUDY RATIONALE 
The use of an intravenous antiplatelet agent including a parenteral P2Y12 inhibitor such as 
cangrelor or a GPI, such as tirofiban, on top of oral therapy with aspirin and a P2Y12 inhibitor 
confers the benefit of a more rapid and stronger antagonism of platelet reactivity, thus bridging the 
initial gap in platelet inhibition associated with the use of oral P2Y12 inhibitors in STEMI patients. 
The association of parenteral and oral antiplatelet agents might therefore mitigate the increased risk 
of early thrombotic complications and improve myocardial salvage conferred by mechanical 
revascularisation. However, the association of multiple potent antithrombotics increases the 
bleeding risk by a magnitude that is depending on patient characteristics and procedural features.  
Cangrelor was shown in a propensity-matched study to be associated to less bleeding risk and 
comparable ischemic protection as compared to GPI administered at standard prolonged post-bolus 
infusion [27]. Whether this postulated differential safety profile of these two agents comes from a 
different degree of ADP-induced inhibition of platelet aggregation, the inherent mechanism of 
action (i.e. ADP as opposed to GP antagonism) or overall duration of treatment (i.e. 2h versus ≥ 12h 



































































The comparative effectiveness of cangrelor and tirofiban on-label regimens in inhibiting platelet 
reactivity remains unknown. Similarly, it remains unclear if the standard loading dose of prasugrel, 
when chewed, might mitigate the absorption delay observed with all oral P2Y12 inhibitors in 




Study design and patient population 
The FABOLUS FASTER is an investigator-initiated, multicentre, open-label, randomized study. 
The study is registered on clinicaltrials.gov NCT02978040, and EudraCT 2017-001065-24. 
The purpose of this study is to compare the efficacy with respect to the inhibition of platelet 
aggregation of cangrelor, tirofiban, or prasugrel, administered as integer or chewed tablets in 
STEMI patients undergoing primary PCI. The study design and flow-chart are summarised in 
Figures 1 and 2. 
Patients undergoing primary PCI due to suspected STEMI are screened at admission and, after 
adequate explanation, those consenting are enrolled in the study by dedicated staff previously 
identified at each participating centre. No screening log is mandated by study and only randomized 
patients with written consent are to be reported. Eligibility criteria are reported in Table 1. Briefly, 
adult patients presenting with STEMI and referred for primary PCI within 12 hours (or 24h if 
ongoing ischemia is demonstrated) will be enrolled. Key exclusion criteria are: unconsciousness or 
other conditions that make the patient incapable of providing informed consent and receiving oral 
loading dose of prasugrel, bleeding diathesis, recent administration of fibrinolytics or GPI or P2Y12 
inhibitors or cangrelor, recent major surgery or bleeding, chronic dialysis, previous intracranial 
haemorrhage, previous stroke or recent TIA, known hypersensitivity to study drugs, chronic oral 



































































Patients are being randomly assigned in a 1:1:1 fashion to tirofiban (≥40 patients, bolus + 2 hour 
infusion, followed by prasugrel at 60 mg loading dose at the time of infusion discontinuation), 
cangrelor (≥40 patients, bolus + 2 hour infusion, followed by prasugrel at 60 mg loading dose at the 
time of infusion discontinuation) or prasugrel 60 mg (≥40 patients, at the beginning of the PCI, 
administered as either integer or chewed tablets). Patients assigned to the prasugrel arm undergo an 
immediate 1:1 sub-randomization to either chewed or integer oral loading dose of prasugrel.  
Randomization is concealed and stratified according to centre and to time from onset of symptoms 
to PCI (<3 hours, 3-6 hours, >6 hours) with blocks of 3 or 6 alternating randomly for the first 
randomization, and stratified according to centre with blocks of 2 or 4 alternating randomly for the 
second randomization, within the electronic data capture system ICE provided by Advice Pharma 
Group (https://advicepharma.com/en/technologies/ice/). 
 
Medications and procedures 
All patients have to receive aspirin before primary PCI (150-300 mg orally or 80-150 mg i.v., then 
81-325 mg daily). Patients allocated to Cangrelor receive the on-label regimen in terms of bolus of 
30 µg/Kg followed by infusion at 4 µg/Kg/min for 2 h (or to the end of PCI). Tirofiban will be 
administrated according to the single high dose bolus (SHDB) of 25 µg/Kg followed by infusion at 
0.15 µg/Kg/min for 2 h (or to the end of PCI) (or an infusion rate of 0.075 µg/Kg/min for patients 
with known creatinine clearance <30 ml/min). At the end of infusion, oral prasugrel at a loading 
dose of 60 mg is to be administrated as integer tablets, followed by 10 mg daily (or 5 mg daily if 
body weight < 60 kg or age > 75 years old) in accordance to the instructions for use and 
international guidelines. In the prasugrel arm, no intravenous anti-platelet drug is to be 
administered. Patients randomized to prasugrel receive either integer or chewed prasugrel at an 
identical loading dose of 60 mg, then 10 mg daily (or 5 mg daily if body weight < 60 kg or age > 75 
years old). In the chewed prasugrel arm, patients are instructed to chew pills for at least 10–15 s 



































































Anticoagulation is to be achieved with concomitant unfractionated heparin (UFH) or enoxaparin 
whereas bivalirudin is not allowed to avoid potential confounding effects. UFH is to be 
administrated as bolus of 50-70 UI/Kg in the two parenteral antiplatelet arms or at 70-100 UI/Kg 
bolus in the prasugrel arm, then adjusted with additional adjunctive boluses in order to achieve an 
activated clotting time (ACT) of at least 250s during the procedure. UFH administration after the 
end of the procedure is discouraged unless clinically indicated.  
Blood samples are obtained at randomization and before the administration of study drug (baseline) 
and then, counting from drug bolus termination (tirofiban and cangrelor arms) or oral loading dose 
of prasugrel, 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours and between 4 to 6 hours thereafter.  
ECG is recorded before and immediately after PCI and 90 minutes thereafter, as well as at 
discharge. Patients providing consent to participate to the imaging sub-study, will undergo cardiac 
magnetic resonance imaging (cMRI) at 3±1 days and 5±1 months. Clinical data collection (vital 
signs, medications, clinical events and serious adverse events) is collected throughout 30 days. 
 
Pharmacodynamic analysis 
LTA analysis remains the gold standard of platelet function evaluation[28], and is being performed 
as previously described[9]. Briefly, at each participating centre, blood samples anticoagulated with 
0.129 mol/l sodium citrate will be collected. Platelet-rich plasma, obtained by centrifuging whole 
blood for 10 min at 70g, will be stimulated with 5 and 20 mol/l ADP and 5 and 15 mol/l 
thrombin receptor agonist peptide (TRAP), and aggregation will be assessed using a light 
transmission aggregometer. The 100% line will be set using platelet-poor plasma and the 0 baseline 
established with platelet-rich plasma (adjusted from 18x109/l up to 30x109/l). Platelet aggregation is 
being evaluated considering the maximal percentage of platelet aggregation in response to stimulus 




































































Multiple electrode aggregometry (Multiplate, Roche Diagnostics, Switzerland) is being performed 
as previously described[29] by using hirudin-anticoagulated whole blood samples. Blood will be 
diluted with saline and then stimulated with ADP and TRAP reagents. After 1:2 dilution of whole 
blood with 0.9% NaCl solution and stirring for 3 min in the test cuvettes at 37°C, ADP, and TRAP 
stimulation will be added and platelet aggregation will be continuously recorded for 6 minutes. This 
measurement simulates platelet adhesion, activation, and aggregation on a metal surface during 
continuous stirring in an ex vivo setting, mimicking the development of stent thrombosis upon 
platelet activation. Changes in impedance are plotted over time resulting in an aggregation curve, 
similarly to LTA, and the efficacy of platelet inhibition is expressed with the area-under-the 
aggregation-curve (AUC) value. 
 
Pharmacokinetic analysis 
A pharmacokinetic analysis will be performed within the Prasugrel arm in order to compare integer 
versus chewed Prasugrel administration. Prasugrel Active Metabolites (PAM) will be measured at 
each time point under the secondary hypothesis that chewed as compared to integer prasugrel will 
lead to higher PAM bioavailability at 30 minutes (and other time points: 15min to 4-6h hours). 
Blood samples for the determination of PAM plasma concentration will be collected into pre-cooled 
EDTA tubes at the established time points (baseline, 15 min, 30 min, 1h, 2h, 3h and 4-6h) and will 
be treated with 25l of 500 mM 3′-methoxyphenacyl bromide in acetonitrile within 30 s of 
collection to derivatize and stabilize the PAM as previously described[14,30]. Centrifugation of the 
sample will be performed within 30 minutes (2800 rpm for 15 min at 4°C), and plasma samples 
prepared from these blood samples will be stored at -20/-80°C in polypropylene tubes until they 
will be shipped to the central laboratory at University Hospital of Verona (LURM) for analysis. 
Plasma concentrations of PAM will be determined using validated liquid chromatography methods 





































































The primary endpoint is the percentage of inhibition of platelet activity (IPA) assessed with light 
transmission aggregometry (LTA) in platelet-rich plasma after the addition of ADP 20 µmol/l at 30 
minutes from drug administration (bolus or oral loading dose). Percentage IPA is defined as 
100%*(baseline platelet aggregregation minus at time t platelet aggregation) / baseline platelet 
aggregration[9]. Baseline is at time 0 minutes just before drug administration, follow-up 
measurements are at time 15 minutes, 30 minutes, 1 hour, 2 hours, 3 hours and 4 to 6 hours since 
drug administration. 
Secondary endpoints include LTA using TRAP at 5 and 15 µmol/l, as well as ADP at 5 µmol/l at all 
different time points and up to 6 hours and ADP at 20 µmol/l at time points before and later than 30 
minutes (15 minutes, 1h, 2h, 3h, 4-6h).  
Other secondary endpoints will include the residual platelet reactivity assessed with Multiplate® 
technology (AUC at impedance aggregometry Multiplate® Electrode Aggregometry in whole 
blood) at all time frames and after ADP and TRAP as agonists.  
For the pharmacokinetic analysis, the time for the maximum plasma concentration (Tmax), 
maximum observed plasma concentration (Cmax), and the area under the plasma concentration 
versus time curve from time 0 to the last measurable concentration (AUC0–t) will be calculated. 
Moreover, to explore early exposure to PAM, AUC from time 0 to 2 h (AUC0–2) will be also 
calculated. 
Adverse clinical ischemic and bleeding events at 48 hours and 30 days will be also collected and 
include: death, cardiac death, non-fatal myocardial infarction, non-fatal stroke, transient ischemic 
attack, urgent target vessel revascularization, unplanned revascularization, definite/probable stent 
thrombosis, bleeding events, net adverse clinical event.  
Other endpoints will be analysed for the pre-specified substudies. 
 



































































The Clinical Trial Unit of Bern provides statistical oversight and guidance. The total number of 
patients with primary endpoint assessment is 120, of whom at least 40 patients in the tirofiban 
group, at least 40 patients in the cangrelor group, and at least 40 patients in the prasugrel group (of 
which at least 20 integer and at least 20 chewed tablets). 
Sample size is calculated to state the non-inferiority of cangrelor compared with tirofiban, 
superiority of both tirofiban and cangrelor compared with chewed prasugrel and to show the 
superiority of chewed prasugrel as compared to integer prasugrel. 
The sample size was determined following these considerations, three primary non-inferiority tests 
each with alpha of 0.05/3 tests = 0.016 and one additional test also with alpha of 0.016 for 
consistency (chewed prasugrel vs integer prasugrel): 
Assuming %IPA with 20 μmol/l ADP at 30 minutes from randomization of at least 94% with i.v. 
antiplatelet therapy, with a standard deviation of 8%, a non-inferiority margin of 9%, with an alpha 
of 0.016, 40 patients per group will give 99% of power to show non-inferiority of cangrelor 
compared to tirofiban. If non-inferiority of cangrelor will not be met, then the superiority of 
tirofiban over cangrelor will be tested (pre-specified secondary endpoint). 
Assuming %IPA with 20 μmol/l ADP at 30 minutes of 55% with chewed prasugrel, with a standard 
deviation of 24% and an alpha of 0.016, this study will have 100% of power to show both 
superiority of Tirofiban (n=40) as compared to chewed Prasugrel (n=20) and superiority of 
Cangrelor (n=40) as compared to chewed Prasugrel (n=20). 
Assuming %IPA with 20 μmol/l ADP at 30 minutes from randomization of 55% with chewed 
prasugrel, with a standard deviation of 24% and an alpha of 0.016, 20 patients per group will give 
82% of power to show superiority of chewed Prasugrel compared with integer Prasugrel. 
These assumptions were largely based on previous evidence[9]. 
The pairwise mean difference in platelet inhibition (difference in %IPA) will be estimated and 
reported with the 95% confidence intervals (Cangrelor vs Tirofiban, Cangrelor vs chewed 



































































time-points since PCI, random effects of site and patient as appropriate), non-inferiority will be 
tested using a z-test. Superiority tests will be conducted on platelet activity (% of IPA at LTA or 
AUC unit at Multiplate, as continuous variables, random effects of site and patient as appropriate) 
using mixed models (including data on all time-points since PCI) with Bonferroni post-hoc test. 
Mixed models will use the appropriate link function according to the type of primary or secondary 
endpoints measured (continuous, binary) and adjust for time-point (minutes to hours since PCI) and 
the interaction between randomized arm and time-point, random effects added of site and patient as 




A pre-specified cMRI substudy will be performed in all patients providing consent to this additional 
study procedure. cMRI will be performed as previously described[31,32]. The relationship with all 
MRI parameters and platelet inhibition at each time point is to be explored. The primary cMRI 
endpoints are the Myocardial salvage Index (MSI) which is defined as Myocardial Salvage/Area at 
risk (MS/AAR) and the extent of intramyocardial haemorrhage. Many other secondary endpoints 
will be analysed, including microvascular obstruction (MVO), and infarct size. Among the pre-
specified sub-analyses, we will explore the relationship between presence and extent of 
intramyocardial haemorrhage and allocated treatment, degree of platelet inhibition, and time to 
presentation.  
An ECG/Angio substudy will investigate the impact of randomized treatment strategy on 
electrocardiographic and angiographic parameters. Anonymized ECGs and angiographies will be 
collected and analysed by a core-lab blinded to treatment strategy. Multiple parameters will be 
extracted and compared among the groups and associated with platelet reactivity. ECG analysis will 



































































A PK/PD substudy will be also performed to explore the role of prasugrel inactive metabolite R-
95913 and its derivatized active metabolite (R-138727, PAM) and their relationship with PD 
profiles. According to the kinetics profile, the threshold exposure that is required to determine a 
meaningful pharmacodynamic response in platelets will be tentatively defined. To this aim, separate 
and cumulative analysis of kinetics data deriving from each time point and any single patients will 
be considered along with the maximum platelet response in ADP-induced platelet aggregation, 
irrespectively of timing of blood sample collection. Time to response, threshold response, and 
maximum response will be considered. 
A cost-effectiveness analysis will be carried out by inputting direct and indirect costs in relation to 
outcomes assessed both in terms of clinical events, surrogate markers of outcomes, such as ST-
segment elevation resolution or infarct size at MRI as well with respect to degree of platelet 
inhibition. 
 
CLINICAL SIGNIFICANCE AND TRANSLATIONAL OUTLOOK 
Ischaemic heart disease is the single most common cause of death worldwide and its frequency is 
increasing. STEMI remains frequent and is associated with substantial rates of mortality. In the last 
years, there was a fall in acute and long-term mortality following STEMI in parallel with greater 
use of reperfusion therapy, PCI, modern antithrombotic therapy, and secondary prevention. 
However, mortality in STEMI patients remains between 4-12% in-hospital and 10% at 1-year 
follow-up. Primary PCI is the standard of treatment of almost all STEMI patients and all patients 
receive DAPT, a combination of aspirin and an oral P2Y12 inhibitor. There is still limited evidence 
with respect to when the oral P2Y12 inhibitor should be initiated in STEMI patients and the only 
randomized trial testing pretreatment in these patients with ticagrelor did not show advantages of 
this strategy compared with administration at the time of PCI. Oral P2Y12 inhibitors are associated 
to delay in the onset of effect in STEMI patients undergoing primary PCI. Therefore, intravenous 



































































and help preventing the increased risk of early thrombotic complications. The FABOLUS FASTER 
study is the first to directly compare the new intravenous P2Y12 inhibitor cangrelor with the 
intravenous GPI tirofiban and the standard oral P2Y12 inhibitor prasugrel. Moreover, this study will 
provide additional pharmacokinetic and pharmacodynamic data on the oral assumption of prasugrel 
through chewed or standard intake of pills that could also be relevant to accelerate the absorption 
and effect of this drug. The study findings will add new relevant insights in the management of 
antiplatelet therapy in patients with STEMI undergoing primary PCI and might be also hypothesis-
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Figure 1. Design of the FABOLUS-FASTER study. 



































































Table 1. Inclusion and exclusion criteria of the FABOLUS-FASTER study. 
INCLUSION CRITERIA 
 Signed Informed Consent  
 Age greater than 18 years old 
 Have symptoms of acute myocardial ischemia (i.e. new persistent anginal pain) that were 
lasting at least 20 min with an electrocardiographic ST-segment elevation > 1 mm in 2 or 
more contiguous ECG leads, or with a new (or presumably new) left bundle branch block 
or ST segment depression of ≥1 mm in ≥2 of leads V1-3 with a positive terminal T wave 
 Referred for primary PCI either within 12 h of symptom onset or between 12 and 24 h after 
onset with evidence of continuing ischemia 
EXCLUSION CRITERIA 
 Unconsciousness 
 Other conditions that make the patient incapable receiving integer loading dose of prasugrel 
 Any contraindication and/or known hypersensitivity or allergy to aspirin, prasugrel, 
intravenous unfractionated heparin, cangrelor, tirofiban 
 Any contraindication to primary PCI 
 Administration of GPI or P2Y12-inhibitors or cangrelor < 7 days  
 Chronic dialysis 
 Recent (< 15 days) or current major bleeding 
 Recent (< 15 days) major surgery 
 Administration of fibrinolytics < 30 days 
 Current use or indication to oral anticoagulant 
 Previous stroke or TIA 
 Inability to follow the procedures of the study (language problems, psychological disorders, 
dementia) or comorbidities associated with less than 6 months survival (active 
malignancies drug or alcohol abuse, etc.) 
 Women who are pregnant or breast feeding or with potential to become pregnant during the 
course of the study (age < 55 years and last menstruation within the last 12 months) and did 
not undergo tubal ligation, ovariectomy or hysterectomy  
 Participation in another study with investigational drug within the 30 days preceding and 
during the present study 
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